Frontlight ResearchEarly access
Taking people in ItalyPhase 1/2
Tests niraparib with abemaciclib in people with late-stage ovarian cancer
Tests two cancer drugs together in adults with ovarian cancer after other treatments.
Key facts
- Who runs it
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 73 people, planned
- Started
- 18 Sept 2024
- Expected to end
- 28 Sept 2029
- Type of study
- Interventional
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with ovarian cancer who need a later-line treatment. It tests niraparib together with abemaciclib.
- Age
- 18 years or older
- Sex
- Women only
Where in Italy
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests niraparib with abemaciclib in people with late-stage ovarian cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 25 June 2026